Major Depressive Disorder (MDD) Clinical Trials

68 recruitingLast updated: June 18, 2026

There are 68 actively recruiting major depressive disorder (mdd) clinical trials across 29 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 4, Early Phase 1, Phase 1. Top locations include Toronto, Ontario, Canada, Prague, Czechia, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Major Depressive Disorder (MDD) Trials at a Glance

68 actively recruiting trials for major depressive disorder (mdd) are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Not Applicable with 29 trials, with the heaviest enrollment activity in Toronto, Prague, and New York. Lead sponsors running major depressive disorder (mdd) studies include Draig Therapeutics Ltd, Emobot, and First Affiliated Hospital of Chongqing Medical University.

Browse major depressive disorder (mdd) trials by phase

Treatments under study

About Major Depressive Disorder (MDD) Clinical Trials

Looking for clinical trials for Major Depressive Disorder (MDD)? There are currently 72 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Major Depressive Disorder (MDD) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Major Depressive Disorder (MDD) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 68 trials

Recruiting
Not Applicable

Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice

Major Depressive Disorder (MDD)
National Science and Technology Council, Taiwan120 enrolled1 locationNCT07462013
Recruiting
Phase 2

Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression

Major Depressive Disorder (MDD)Probiotic Intervention
First Affiliated Hospital of Chongqing Medical University60 enrolled2 locationsNCT07539805
Recruiting
Phase 3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

DepressionDepression - Major Depressive DisorderDepression in Adults+3 more
Cybin IRL Limited330 enrolled67 locationsNCT06793397
Recruiting
Phase 2

Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression

Major Depressive Disorder (MDD)Probiotic Intervention
First Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT07645157
Recruiting
Phase 2

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.153 enrolled21 locationsNCT07284667
Recruiting
Phase 2

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

DepressionMajor Depressive Disorder (MDD)Major Depressive Episode (MDE)
Tonix Pharmaceuticals, Inc.360 enrolled25 locationsNCT07621237
Recruiting

Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental Illness

Major Depressive Disorder (MDD)Anxiety DisorderAlcohol Use Disorder (AUD)
Huashan Hospital680 enrolled3 locationsNCT07571226
Recruiting
Phase 2

Inhaled DMT for Major Depressive Disorder

SuicideSuicidal IdeationMajor Depression+2 more
Universidade Federal do Rio Grande do Norte140 enrolled5 locationsNCT07562191
Recruiting
Phase 2

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Major Depressive Disorder (MDD)
Draig Therapeutics Ltd118 enrolled2 locationsNCT07610473
Recruiting
Not Applicable

Accelerated iTBS for Major Depression

Major Depressive Disorder (MDD)Treatment Resistant Depression (TRD)
Istanbul University - Cerrahpasa35 enrolled1 locationNCT07603804
Recruiting

Predictors of Relapse in Major Depressive Disorder (PERFORM-D)

Major Depressive Disorder (MDD)
Abraham Nunes252 enrolled8 locationsNCT06746155
Recruiting

Validation of the CIDI 5.0 Against the SCID-5 for Lifetime Mental Disorders

Major Depressive Disorder (MDD)Posttraumatic Stress Disorder (PTSD)Generalized Anxiety Disorder (GAD)
The University of Hong Kong300 enrolled1 locationNCT07604753
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled59 locationsNCT07065240
Recruiting
Phase 2Phase 3

Understanding and Treating Suicidal Ideation With Ketamine

Suicidal IdeationMajor Depressive Disorder (MDD)
The Royal's Institute of Mental Health Research36 enrolled1 locationNCT06891300
Recruiting
Not Applicable

Mechanisms Of Orbitofrontal Stimulation in Depression

Major Depressive Disorder (MDD)
Subha Subramanian80 enrolled1 locationNCT07230990
Recruiting
Phase 2

Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)Insomnia Comorbid to Psychiatric Disorder
Unity Health Toronto30 enrolled1 locationNCT06843187
Recruiting
Not Applicable

Home-Based tDCS for Depression in BPD

Major Depressive Disorder (MDD)Borderline Personality Disorders
Ciusss de L'Est de l'Île de Montréal60 enrolled1 locationNCT06972368
Recruiting
Phase 2

Psilocybin Therapy for Psychological Distress in Palliative Patients

COPD, Chronic Obstructive Pulmonary DiseaseMajor Depressive Disorder (MDD)ALS (Amyotrophic Lateral Sclerosis)+2 more
University Medical Center Groningen108 enrolled4 locationsNCT06782724
Recruiting
Phase 2

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Major Depressive Disorder (MDD)
Draig Therapeutics Ltd300 enrolled40 locationsNCT07300969
Recruiting
Phase 2

A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression

Major Depressive Disorder (MDD)
Daniel Lindqvist12 enrolled1 locationNCT07396272